Literature DB >> 26321184

Self-Destruct Genetic Switch to Safeguard iPS Cells.

Zoltán Ivics1.   

Abstract

Mesh：

Substances：

Year:  2015        PMID： 26321184      PMCID： PMC4817888          DOI： 10.1038/mt.2015.139

Source DB:  PubMed          Journal:  Mol Ther        ISSN： 1525-0016            Impact factor:   11.454


× No keyword cloud information.
  19 in total

1.  In vivo selection using a cell-growth switch.

Authors:  L Jin; H Zeng; S Chien; K G Otto; R E Richard; D W Emery; C A Blau
Journal:  Nat Genet       Date:  2000-09       Impact factor: 38.330

2.  An inducible caspase 9 safety switch for T-cell therapy.

Authors:  Karin C Straathof; Martin A Pulè; Patricia Yotnda; Gianpietro Dotti; Elio F Vanin; Malcolm K Brenner; Helen E Heslop; David M Spencer; Cliona M Rooney
Journal:  Blood       Date:  2005-02-22       Impact factor: 22.113

Review 3.  Suicide genes for cancer therapy.

Authors:  Daniel Portsmouth; Juraj Hlavaty; Matthias Renner
Journal:  Mol Aspects Med       Date:  2007-01-10

4.  Suicide gene therapy with adenoviral delivery of HSV-tK gene for patients with local recurrence of prostate cancer after hormonal therapy.

Authors:  Yasutomo Nasu; Takashi Saika; Shin Ebara; Nobuyuki Kusaka; Haruki Kaku; Fernando Abarzua; Daisuke Manabe; Timothy C Thompson; Hiromi Kumon
Journal:  Mol Ther       Date:  2007-02-27       Impact factor: 11.454

5.  In vivo gene therapy for colon cancer using adenovirus-mediated, transfer of the fusion gene cytosine deaminase and uracil phosphoribosyltransferase.

Authors:  G A Chung-Faye; M J Chen; N K Green; A Burton; D Anderson; V Mautner; P F Searle; D J Kerr
Journal:  Gene Ther       Date:  2001-10       Impact factor: 5.250

6.  Cancer gene therapy with iCaspase-9 transcriptionally targeted to tumor endothelial cells.

Authors:  W Song; Z Dong; T Jin; M G Mantellini; G Núñez; J E Nör
Journal:  Cancer Gene Ther       Date:  2008-06-20       Impact factor: 5.987

Review 7.  5-fluorouracil: mechanisms of action and clinical strategies.

Authors:  Daniel B Longley; D Paul Harkin; Patrick G Johnston
Journal:  Nat Rev Cancer       Date:  2003-05       Impact factor: 60.716

8.  Induction of pluripotent stem cells from adult human fibroblasts by defined factors.

Authors:  Kazutoshi Takahashi; Koji Tanabe; Mari Ohnuki; Megumi Narita; Tomoko Ichisaka; Kiichiro Tomoda; Shinya Yamanaka
Journal:  Cell       Date:  2007-11-30       Impact factor: 41.582

9.  Treatment of sickle cell anemia mouse model with iPS cells generated from autologous skin.

Authors:  Jacob Hanna; Marius Wernig; Styliani Markoulaki; Chiao-Wang Sun; Alexander Meissner; John P Cassady; Caroline Beard; Tobias Brambrink; Li-Chen Wu; Tim M Townes; Rudolf Jaenisch
Journal:  Science       Date:  2007-12-06       Impact factor: 47.728

Review 10.  Deconstructing stem cell tumorigenicity: a roadmap to safe regenerative medicine.

Authors:  Paul S Knoepfler
Journal:  Stem Cells       Date:  2009-05       Impact factor: 6.277
View more
  3 in total

1.  Metabolic engineering generates a transgene-free safety switch for cell therapy.

Authors:  Volker Wiebking; James O Patterson; Renata Martin; Monica K Chanda; Ciaran M Lee; Waracharee Srifa; Gang Bao; Matthew H Porteus
Journal:  Nat Biotechnol       Date:  2020-07-13       Impact factor: 54.908

2.  Safe harbor-targeted CRISPR-Cas9 homology-independent targeted integration for multimodality reporter gene-based cell tracking.

Authors:  John J Kelly; Moe Saee-Marand; Nivin N Nyström; Melissa M Evans; Yuanxin Chen; Francisco M Martinez; Amanda M Hamilton; John A Ronald
Journal:  Sci Adv       Date:  2021-01-20       Impact factor: 14.136

Review 3.  Manufacturing clinical-grade human induced pluripotent stem cell-derived beta cells for diabetes treatment.

Authors:  Lay Shuen Tan; Juin Ting Chen; Lillian Yuxian Lim; Adrian Kee Keong Teo
Journal:  Cell Prolif       Date:  2022-04-26       Impact factor: 8.755
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.